Literature DB >> 36105

Antitumor drug-protein interactions. Binding of 1-beta-D-arabinofuranosyl cytosine to albumin and chemically modified albumin.

M Szekerke, M Horváth, F Hudecz.   

Abstract

Equilibrium dialysis measurements were carried out to study the binding of 1-beta-D-arabinofuranosyl cytosine (ara-C) to human and bovine serum albumin (HSA, BSA) and to chemically modified albumin. The binding of 4-phenylbutyric acid to HSA was studied, too. Binding data were presented as Scatchard plots. There are two types of binding sites of different affinity for ara-C both on HSA and BSA. The relatively small value of affinity constant indicates that the pharmacological properties of ara-C might not be influenced very strongly by the HSA interaction or by competitive binding of other drugs. Selective chemical modifications of HSA with diethylpyrocarbonate (DEP) or o-nitrophenylsulfenyl chloride (NPS-Cl) reduce significantly the affinity of the strong binding area. On the other hand, the attachment of poly-alpha-L-glutamyl or poly-DL-alanyl side-chains to BSA increase the number of the strong and secondary binding sites and also the affinity at the first group of sites. Experimental results suggest a correlation between the binding affinity and therapeutic efficacy of various cytotoxic drug-protein complexes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 36105

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  2 in total

Review 1.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Modification of human serum albumin binding of methotrexate by folinic acid and certain drugs used in cancer chemotherapy.

Authors:  P Coassolo; M Valentin; M Bourdeaux; C Briand
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.